KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

DDW-1.0-o

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Media Contact for Kizoo:

Frank Schueler
Managing Director
Kizoo Technology Capital
fs@kizoo.com

Media Contact for Underdog:

Mike Kope
Co-CEO
Underdog Pharmaceuticals Inc
press@underdogpharma.com

Share on facebook
Share on twitter
Share on reddit
Share on linkedin
Share on whatsapp
Share on email

Underdog News:

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Read More »

Kizoo Portfolio Company Underdog Closes $10M Financing Round

Underdog Pharmaceuticals, a key investment of Michael Greve’s rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Kizoo led the company’s Series Seed II round, which saw participation from both existing and new investors.

Underdog was recently awarded the Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP). This will enable faster patient access to its groundbreaking treatment for the prevention of heart attacks and stroke. The company expects to begin clinical trials in 2023.

Read More »

7-Ketocholesterol in disease and aging

Scientists from Underdog Pharmaceuticals, in conjunction with Professor Jay Jerome of Vanderbilt University Medical Center, have published an article in the journal Redox Biology, covering the role of the toxic biomolecule 7-ketocholesterol, especially in the

Read More »

© 2021 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com

© 2022 Underdog Pharmaceuticals – ALL RIGHTS RESERVED

Site developed by Moonburn.com